Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 16];8(6):s442. Available from: https://skin.dermsquared.com/skin/article/view/3141